To assess the safety and biological efficacy of therapeutically administered most closely
HLA-matched third party donor-derived specific cytotoxic T lymphocytes (CTLs) targeting
cytomegalovirus (CMV) or Adenovirus (Adv) or Epstein Barr virus (EBV) or fungi including
Aspergillus and Candida species for the treatment of viral infection following allogeneic
blood or marrow stem cell or solid organ transplantation.